Tryp Therapeutics Inc.

 

 

Apr 20, 2021
Tryp Therapeutics Reports on Key Milestones for 2021
Apr 15, 2021
Tryp Therapeutics to Host Investor Day on April 22
Apr 5, 2021
Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility
Apr 1, 2021
Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer
Mar 18, 2021
Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics
Mar 9, 2021
Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer
Mar 4, 2021
Tryp Therapeutics Announces Application to List on OTCQB
Feb 24, 2021
Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference
Feb 18, 2021
Tryp Therapeutics Completes $2 Million Strategic Financing
Feb 16, 2021
Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program
Feb 11, 2021
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
Feb 8, 2021
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller
Feb 5, 2021
Tryp Therapeutics Announces Strategic Investment of $2,000,000
Feb 3, 2021
Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman
Feb 2, 2021
Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board
Jan 19, 2021
Tryp Therapeutics Invited to Present at "Investing in Psychedelics" Conference
Jan 13, 2021
Tryp Therapeutics Invited to Present at Global Healthcare & Psychedelic Conferences
Jan 7, 2021
Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board

Sign up to Download our Investor Presentation

© 2021
All rights reserved.
Disclaimer